Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemprocitinib (LNK01001) in moderate to severe atopic dermatitis
NCT06085521Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zemprocitinib in atopic dermatitis (AD) (3 arms), sponsored by Lynk Pharmaceuticals. Primary endpoint: Percent Change from Baseline in Eczema Area and Severity Index (EASI) Score at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
zemprocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06085521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085521.